**Question:** Pyle's disease has,

A. hypercalcemia
B. hypocalcemia
C. hypoparathyroidism
D. hyperphosphatemia

**Correct Answer:** Pyle's disease is characterized by hypercalcemia.

**Core Concept:** Pyle's disease, also known as idiopathic hypercalcemia of malignancy, is a complication of certain types of cancer. It occurs when malignant cells secrete parathyroid hormone-related peptide (PTHrP), which stimulates the kidneys to retain calcium and the bones to release calcium, leading to increased blood calcium levels (hypercalcemia).

**Why the Correct Answer is Right:** Hypercalcemia is the correct answer because it directly relates to the underlying mechanism of Pyle's disease. PTHrP, a hormone produced by malignant cells, mimics the actions of parathyroid hormone (PTH), which is responsible for regulating calcium homeostasis in the body. PTHrP stimulates the kidneys to retain calcium and the bones to release calcium, consequently leading to hypercalcemia.

**Why Each Wrong Option is Incorrect:**

B. Hypocalcemia (low blood calcium levels) is incorrect because Pyle's disease results from high blood calcium levels, not low ones.

C. Hypoparathyroidism (low PTH levels) is incorrect because PTHrP, a paracrine hormone secreted by malignant cells, mimics the actions of PTH in Pyle's disease, not its inverse.

D. Hyperphosphatemia (high blood phosphate levels) is incorrect because PTHrP's primary action is to elevate blood calcium levels, not phosphate levels.

**Clinical Pearl:** The correct identification of Pyle's disease is crucial, as it guides appropriate management strategies and prognosis. Hypercalcemia is typically managed through anti-cancer treatment, hydration, and diuretic therapy. Monitoring calcium levels is essential for evaluating treatment efficacy and preventing complications associated with hypercalcemia, such as kidney stones, hypercalcemic crises, and osteoporosis.